Industry veterans John Bennett and Scott Jackson expand business and commercial development focus at Celator as company advances pipeline of combination chemotherapies.
Scott Jackson earned a MBA in 1995 from the University of Notre Dame
Celator Pharmaceuticals, a biotechnology company working to develop combination chemotherapies to treat different types of cancer, today announced two new additions to the company’s senior management team. John Bennett has joined Celator as the new Head of Business Development, and Scott Jackson has joined the company as Head of Commercial Development.
Scott Jackson has nearly 20 years of pharmaceutical marketing and sales experience, including extensive commercialization activities for oncology products. At Celator he will develop and manage commercialization strategies for the company’s products. Previously Mr. Jackson was responsible for product marketing at YM BioSciences. Prior to that he held positions of increasing responsibility at Centocor (Johnson & Johnson), ImClone Systems, SmithKline Beecham, and Eli Lilly. He has an M.B.A. from The University of Notre Dame and a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science.
“Both John and Scott bring extensive experience in pharmaceutical business development and product commercialization to Celator. As we continue to advance our pipeline and pursue additional product development and licensing opportunities based on our CombiPlex technology platform, their expertise will play a key role in positioning us for commercial success in the years ahead,” said Andrew Janoff, Ph.D., CEO of Celator Pharmaceuticals.